Vericel Corp 2021 SR
The report highlights Vericel's inaugural ESG disclosures for the 2021 fiscal year, focusing on its leadership in advanced cell therapies like MACI and Epicel. Key achievements include a 26% total revenue growth to $156.2 million and the establishment of a Diversity and Inclusion Advisory Committee. The company announced plans for a new LEED Gold and Fitwel Level 2 certified manufacturing facility in Burlington, Massachusetts, expected to open in 2025. Vericel also reported on its workforce diversity, with 37% female representation and 32% non-white employees, while aligning its reporting with SASB standards for Medical Equipment and Supplies.
Company: Vericel Corp
Sector: Health Care
Country: United States
Year: 2021
Type: SR
Pages: 25
Vericel Corp
ESG Report
The report highlights Vericel's inaugural ESG disclosures for the 2021 fiscal year, focusing on its leadership in advanced cell therapies like MACI and Epicel. Key achievements include a 26% total revenue growth to $156.2 million and the establishment of a Diversity and Inclusion Advisory Committee. The company announced plans for a new LEED Gold and Fitwel Level 2 certified manufacturing facility in Burlington, Massachusetts, expected to open in 2025. Vericel also reported on its workforce diversity, with 37% female representation and 32% non-white employees, while aligning its reporting with SASB standards for Medical Equipment and Supplies.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Employees